|
tbar.gif
|
|
Brain,
Ovarian, and Lung Cancers Are First in Project to Identify
Cancer-Related Genes
September 13, 2006--The
National Institutes of Health announced that brain tumors, ovarian
cancer, and lung cancer will be the first subjects in the Cancer
Genome Atlas project, which aims to sequence all the genetic
changes that lead to cancer. According to acting director John
Niederhuber of the National Cancer Institute, "Results from
the Cancer Genome Atlas Pilot Project may provide the results we
need to detect cancer early, in its most treatable stage, and
provide new targets for the development of specific
therapies." NIH hopes the Cancer Genome Atlas project will
pinpoint hundreds or thousands of new genes involved in cancer,
and provide a basis for better drugs to treat it and tools to
diagnose it. Reuters |
|
|
|
OPINION |
Expanding Cancer Targets
By Irena Melnikova
Bio-IT World | The World Health Organization estimates that by 2020, there will be 16 million new cancer cases every year, and there is a continual need for novel therapies that will command premium pricing. In addition, as new medicines prolong life, some current short-term agents could see extended usage, thereby generating additional sales. These forces are driving the expansion of the global oncology market.
Despite the wealth of potential targets, current drugs address only a handful of the best-characterized oncogenesis pathways, but the number of targets is growing exponentially. While not all of these targets will work, several have the potential to improve efficacy for many tumor types, and contribute significantly to the oncology market over the next five years.
Read more.
|
|
|
